StockData
MaxCyte, Inc. logo

MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3065% below fair value
$1.17−0.01 (-0.85%)

Close on Nov 17, 2026Market cap $120.75MP/E –Yield –

MaxCyte gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

MaxCyte's gross profit for the twelve months ending Jun 30, 2026 was $24.60M, down 13.8% year over year. For fiscal 2025 it was $26.80M, down 15.0% from the year before. The highest annual figure on record is $39.16M in fiscal 2022.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$26.80M-15.0%
FY2024Dec 31, 2024$31.53M-13.7%
FY2023Dec 31, 2023$36.55M-6.7%
FY2022Dec 31, 2022$39.16M+29.5%
FY2021Dec 31, 2021$30.25M+29.2%
FY2020Dec 31, 2020$23.40M+22.4%
FY2019Dec 31, 2019$19.12M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.60M-19.9%
Q1 FY2026Mar 31, 2026$8.08M-9.1%
Q4 FY2025Dec 31, 2025$5.69M-11.3%
Q3 FY2025Sep 30, 2025$5.23M-16.1%
Q2 FY2025Jun 30, 2025$6.99M-21.8%
Q1 FY2025Mar 31, 2025$8.89M-10.5%
Q4 FY2024Dec 31, 2024$6.41M-54.5%
Q3 FY2024Sep 30, 2024$6.24M-13.5%
Q2 FY2024Jun 30, 2024$8.94M+16.6%
Q1 FY2024Mar 31, 2024$9.94M+31.2%
Q4 FY2023Dec 31, 2023$14.09M+29.6%
Q3 FY2023Sep 30, 2023$7.21M-22.2%
Q2 FY2023Jun 30, 2023$7.67M-9.7%
Q1 FY2023Mar 31, 2023$7.58M-28.0%
Q4 FY2022Dec 31, 2022$10.88M+21.9%
Q3 FY2022Sep 30, 2022$9.27M+0.9%
Q2 FY2022Jun 30, 2022$8.49M+34.2%
Q1 FY2022Mar 31, 2022$10.52M+81.4%
Q4 FY2021Dec 31, 2021$8.93M+17.3%
Q3 FY2021Sep 30, 2021$9.20M+52.5%
Q2 FY2021Jun 30, 2021$6.32M+35.0%
Q1 FY2021Mar 31, 2021$5.80M–
Q4 FY2020Dec 31, 2020$7.61M–
Q3 FY2020Sep 30, 2020$6.03M–
Q2 FY2020Jun 30, 2020$4.68M–

More MaxCyte figures

See a number that looks wrong?